Clinical Trial Update: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

A Phase 4 open-label study assessed whether early response to certolizumab pegol can predict longer-term outcomes in rheumatoid arthritis; results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Italy s.p.a. | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2016-03-23